Approval Process Initiated for Pediatric Formulation of Dovato for HIV Treatment
ViiV Healthcare has submitted applications to the EMA and FDA to expand the use of Dovato (dolutegravir/lamivudine) for the treatment of HIV in younger children. The EMA validated the application on May 11, 2026, paving the way for new therapy options for pediatric patients.
'Pediatric Dovato': Why ViiV Healthcare's Application Signals a Shift in Pediatric HIV Therapy Philosophy
On May 11, 2026, the European Medicines Agency (EMA) confirmed the validation of ViiV Healthcare's marketing application to expand the use of Dovato (dolutegravir/lamivudine) to younger age groups. The FDA is reviewing a similar dossier. At first glance, this is a standard regulatory procedure. But behind this event lies a fundamental shift in pediatric HIV medicine that will redefine treatment standards for hundreds of thousands of children over the next three years.
The Core: What's Really Happening
This is not just about lowering the age threshold for an existing drug. ViiV Healthcare is seeking approval for Dovato in children aged 2 to 12 years who currently lack access to a two-drug regimen in a single tablet. For the 2–15 age group, dosing is weight-based, starting from 6 kg—essentially the pediatric minimum for oral therapy.
The clinical basis for the application is the D3 (Penta21) study, sponsored by the PENTA Foundation, involving 386 children aged 2 to 15 years. This Phase 2/3 trial started in April 2022 with an estimated completion date of September 30, 2026. The design compares the two-drug regimen DTG/3TC with standard triple therapy in virologically suppressed patients. The primary endpoint is maintenance of suppression at 96 weeks.
What's really happening in the market: ViiV Health is betting on a de-escalation strategy in pediatrics. Fewer drugs mean less toxicity and fewer long-term metabolic consequences. This is the same logic that made Dovato a blockbuster in the adult segment ($2.5 billion in 2025). Now the company is applying it to children.
Timeline and Context
The story has unfolded sequentially. The IMPAACT 2017 study, presented at CROI 2026 in Denver, showed 96-week data on long-term suppression in children on DTG-containing regimens. Concurrently, IMPAACT 2036 provided pharmacokinetic data and safety profiles for younger age groups. ViiV also presented initial results on viral suppression in children under 5 receiving DTG regimens.
A separate line of evidence comes from the LoDoCA study in Lesotho, where 245 children were switched from lopinavir/ritonavir to dolutegravir. The result: 96% of adolescents and 99% of parents reported being 'much more satisfied' with the new treatment. This is not clinical efficacy but an adherence signal critical for pediatrics.
The parallel LIFE2Scale study in Mozambique and Tanzania showed that infants receiving DTG regimens from birth achieved viral suppression of 73.7% by 6 months versus 31.1% on lopinavir—a twofold superiority (RR 2.36, p=0.001). These are data from the very bottom of the age pyramid—from 4 weeks and 3 kg of weight.
Who Wins and Who Loses
Winners:
ViiV Healthcare (majority-owned by GSK) gains a strategic asset worth an additional $800–900 million in annual sales by 2029. The pediatric HIV therapy segment is roughly $1.2 billion globally, and Dovato aims to become the first-line standard.
Children aged 2 to 12 and their parents get the first approved fully oral two-drug fixed-dose combination. Currently, younger children often have to take three separate drugs, frequently as granules or suspensions with unpleasant tastes. One dispersible tablet a day is a radical simplification.
Healthcare systems in resource-limited countries benefit economically. ViiV historically grants voluntary licenses through the Medicines Patent Pool for 118 countries, home to 98.7% of HIV-infected children. A two-drug regimen is cheaper than triple therapy, simpler in the supply chain, and easier for healthcare worker training.
Losers:
Gilead Sciences with Biktarvy. The company has sequentially expanded pediatric indications: in 2019 from 25 kg, in 2021 from 14 kg, and in 2025 additional indications for suppressed patients. But Biktarvy remains a three-drug regimen (bictegravir/emtricitabine/tenofovir alafenamide). In the pediatric space, the de-escalation argument—'fewer drugs, less toxicity'—is particularly compelling for parents and pediatricians.
Manufacturers of lopinavir/ritonavir, primarily AbbVie with Kaletra. Data from LIFE2Scale and LoDoCA show that DTG regimens outperform LPV/r in efficacy and tolerability. Lopinavir in pediatrics is a fading era. LPV/r granules, which require refrigeration and have a bitter taste, lose to DTG on all fronts except one: they are already approved and familiar to clinicians.
What the Media Isn't Saying
Insight One: Timing Against Biktarvy.
On July 30, 2025, the FDA approved expanded indications for Biktarvy in treatment-experienced patients. The exclusivity end date for the pediatric indication for weight 14–25 kg is October 7, 2028. This means Gilead loses exclusivity in the pediatric segment in about two and a half years. ViiV Health timed its application to gain approval and build market share precisely when the competitor's patent protection expires. This is a classic 'patent cliff ambush'—a tactical maneuver rarely discussed in press releases.
Insight Two: Dispersible Form as a Technological Barrier.
Developing the pediatric formulation of DTG/3TC required solving complex technical challenges: ensuring stability of the combination in a dispersible matrix, masking taste (children won't swallow a bitter pill), and ensuring accurate dosing across weight ranges from 6 kg. This creates an additional barrier for generic manufacturers. Even after voluntary licenses through MPP, generic companies will need 18–24 months to master the technology. ViiV gains an effective monopoly for 3–4 years in the pediatric DTG/3TC segment, even with formally open licensing.
Insight Three: Signal on Neurocognitive Development.
The D3 (Penta21) study includes a sub-endpoint that is rarely discussed: neurocognitive assessment of children on DTG/3TC versus triple therapy. DTG crosses the blood-brain barrier better than many antiretroviral drugs. This potentially means better protection of the CNS from HIV-associated damage—a critical factor for the developing brain. However, CNS penetration can also cause side effects: sleep disturbances, dizziness. The LoDoCA study specifically monitored sleep in children switched to DTG—no significant changes were found. But long-term cognitive outcomes remain an open question, and its resolution will determine the fate of pediatric DTG therapy for the next decade.
Forecast: Next 30 Days and 90 Days
30 Days (by mid-June 2026):
The EMA will begin accelerated review. Given the involvement of the PENTA Foundation—Europe's largest pediatric research network—and the availability of IMPAACT data, the process will proceed without major delays. The FDA, for its part, will look to the CROI 2026 results. No public hearings are expected during this period, but ViiV Health may issue an additional press release detailing pharmacokinetic data for the 6–14 kg weight group.
90 Days (by mid-August 2026):
This is a key period for the FDA. I estimate the probability of priority review at over 70%: pediatric HIV drugs traditionally receive accelerated review. If priority review is granted, an FDA decision is expected in October–November 2026. The EMA typically moves in sync with the FDA on pediatric indications.
The D3 (Penta21) study will continue collecting data for the 96-week analysis. The expected completion date is September 30, 2026. This means that by the time regulatory decisions are made, long-term efficacy and safety data will be available.
Structural Forecast for 2027–2028:
If Dovato receives pediatric approval, the standard of pediatric HIV therapy will change irreversibly. Triple regimens (Biktarvy, Triumeq) will retain their place for treatment-experienced patients with complex resistance profiles, but for naive and virologically suppressed children, the two-drug DTG/3TC will become the therapy of choice. The economic impact on global health: a reduction in pediatric treatment costs of $120–180 million annually by eliminating the third component and simplifying logistics. But the real gain is not measured in dollars: children who start treatment earlier and adhere consistently have a chance at normal life expectancy and quality of life—something infectious disease pediatricians could only dream of two decades ago.
— Editorial Team
